Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder
(MedPage Today) -- SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.
From baseline to 24 weeks...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Bleeding | Cancer & Oncology | Epistaxis (Nosebleeds) | Genetics | Hematology | Hereditary Hemorrhagic Telangiectasia